Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05462717 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv23
  2. Primary completion date: Nov 2024 to Mar 31, 2027 Completion date: Dec 2025 to Sep 30, 2027 · Eligibility criteria expanded, about 6 wordsv22 Show 2 more changesShow less
    • Completion date: Dec 2025 to Sep 30, 2027
    • Eligibility criteria expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv21
  4. Trial status: Recruiting to Active, Not Recruiting Site details revised at 64 of 64 sitesv20 Show 1 more changeShow less
    • Site details revised at 64 of 64 sites
  5. Study sites: 56 to 64v19
Show 17 earlier versionsHide 17 earlier versions
  1. Enrollment target: 117 to 222v18
  2. Study sites: 53 to 56v17
  3. Study sites: 49 to 53v16
  4. Site details revised at 2 of 49 sitesv15
  5. Study sites: 46 to 49v14
  6. Study sites: 44 to 46v13
  7. Study sites: 31 to 44v12
  8. Study sites revised (31)v11 See this version in full on ClinicalTrials.gov ↗
  9. Study sites: 17 to 31v10
  10. Study sites: 12 to 17v9
  11. Study sites: 9 to 12v8
  12. Study sites: 6 to 9v7
  13. Start date changed from estimate of Sep 2022 to Sep 19, 2022v6
  14. Study sites: 5 to 6v5
  15. Study sites: 3 to 5v4
  16. Study sites: 2 to 3v3
  17. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2v2 Show 1 more changeShow less
    • Study sites: 0 to 2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Revolution Medicines, Inc.
16 trials monitored
See 1 trial at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 1 more disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
Trial Details
NCT Number NCT05462717
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Enrollment 222 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov